TY - JOUR
T1 - A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and caucasian cancer patients
T2 - CALGB 9871
AU - Lewis, Lionel D.
AU - Miller, Antonius A.
AU - Rosner, Gary L.
AU - Dowell, Jonathan E.
AU - Valdivieso, Manuel
AU - Relling, Mary V.
AU - Egorin, Merrill J.
AU - Bies, Robert R.
AU - Hollis, Donna R.
AU - Levine, Ellis G.
AU - Otterson, Gregory A.
AU - Millard, Frederick
AU - Ratain, Mark J.
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Purpose: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients. We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients. Experimental Design: We investigated population pharmacokinetics and pharmacodynamics and the pharmacogenetics of CYP3A4, CYP3A5, and ABCB1 in African-American and Caucasian cancer patients who received docetaxel 75 or 100 mg/m2 as a 1-h i.v. infusion. Plasma docetaxel concentrations were measured by high-performance liquid chromatography. Clinical toxicity and absolute neutrophil count (ANC) were monitored on days 8, 15, and 22 postadministration of docetaxel. Using a limited sampling strategy and nonlinear mixed-effects modeling, each patient's docetaxel clearance was estimated. Genotyping for known polymorphisms in CYP3A4, CYP3A5, and ABCB1 was done. Results: We enrolled 109 patients: 40 African-Americans (26 males; 14 females), with a median age of 61 years (range, 29-73), and 69 Caucasians (43 males; 26 females), with a median age of 63 years (range, 38-81). There was no difference in the geometric mean docetaxel clearance between African-American patients [40.3 L/h; 95% confidence interval (95% CI), 19.3-84.1] and Caucasian patients (41.8 L/h; 95% CI, 22.0-79.7; P = 0.6). We observed no difference between African-American and Caucasian patients in the percentage decrease in ANC nor were docetaxel pharmacokinetic parameters related to the genotypes studied. Conclusions: Docetaxel clearance and its associated myelosuppression were similar in African-American and Caucasian cancer patients.
AB - Purpose: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared with Caucasian patients. We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients. Experimental Design: We investigated population pharmacokinetics and pharmacodynamics and the pharmacogenetics of CYP3A4, CYP3A5, and ABCB1 in African-American and Caucasian cancer patients who received docetaxel 75 or 100 mg/m2 as a 1-h i.v. infusion. Plasma docetaxel concentrations were measured by high-performance liquid chromatography. Clinical toxicity and absolute neutrophil count (ANC) were monitored on days 8, 15, and 22 postadministration of docetaxel. Using a limited sampling strategy and nonlinear mixed-effects modeling, each patient's docetaxel clearance was estimated. Genotyping for known polymorphisms in CYP3A4, CYP3A5, and ABCB1 was done. Results: We enrolled 109 patients: 40 African-Americans (26 males; 14 females), with a median age of 61 years (range, 29-73), and 69 Caucasians (43 males; 26 females), with a median age of 63 years (range, 38-81). There was no difference in the geometric mean docetaxel clearance between African-American patients [40.3 L/h; 95% confidence interval (95% CI), 19.3-84.1] and Caucasian patients (41.8 L/h; 95% CI, 22.0-79.7; P = 0.6). We observed no difference between African-American and Caucasian patients in the percentage decrease in ANC nor were docetaxel pharmacokinetic parameters related to the genotypes studied. Conclusions: Docetaxel clearance and its associated myelosuppression were similar in African-American and Caucasian cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=34250683752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250683752&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-06-2345
DO - 10.1158/1078-0432.CCR-06-2345
M3 - Article
C2 - 17545536
AN - SCOPUS:34250683752
SN - 1078-0432
VL - 13
SP - 3302
EP - 3311
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 11
ER -